Natural Products
| Catalog No. | Information |
| CFN60063 | Ruxolitinib (INCB018424) Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis. |
| CFN60064 | SCH772984 SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells. |
| CFN60065 | Buparlisib (BKM120) Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. |
| CFN60066 | Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. |
| CFN60067 | Pictilisib (GDC-0941) Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. |
| CFN60068 | Ipatasertib (GDC-0068) Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. |
| CFN60069 | Daclatasvir (BMS-790052) Daclatasvir (BMS-790052, EBP883) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. |
| CFN60070 | Vistusertib (AZD2014) Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). AZD2014 showed no or weak binding to the majority of kinases when tested at 1 μM. AZD2014 induces proliferation suppression, apoptosis, cell cycle arrest, and autophagy in HCC cells with antitumor activity. |
| CFN60071 | Silmitasertib (CX-4945) |
| CFN60072 | PF-04691502 |
| CFN60073 | Ceritinib (LDK378) |
| CFN60074 | AZD4547 |
| CFN60075 | Bemcentinib (R428) |
| CFN60076 | Fasudil Hydrochloride |
| CFN60077 | LDN193189 |
| CFN60078 | LDN-193189 HCl |
| CFN60079 | Ixazomib (MLN2238) |
| CFN60080 | LDC000067 |
| CFN60081 | Torkinib (PP242) |
| CFN60082 | BIX02189 |
| CFN60083 | Plerixafor (AMD3100) |
| CFN60084 | Dacomitinib (PF-00299804) |
| CFN60085 | IWR-1-endo |
| CFN60086 | CX-5461 |
| CFN60087 | Cabozantinib malate (XL184) |
| CFN60088 | Capivasertib (AZD5363) |
| CFN60089 | A66 |
| CFN60090 | NSC 23766 |
| CFN60091 | Talazoparib (BMN 673) |
| CFN60092 | 3-Deazaneplanocin A (DZNeP) HCl |
| CFN60093 | Ribociclib (LEE011) |
| CFN60094 | WZ4002 |
| CFN60095 | Alpelisib (BYL719) |
| CFN60096 | Dorsomorphin dihydrochloride |
| CFN60097 | Gemcitabine HCl |
| CFN60098 | Torin 1 |
| CFN60099 | Sapanisertib (MLN0128) |
| CFN60100 | Thiazovivin |
| CFN60101 | Berzosertib (VE-822) |
| CFN60102 | Wnt-C59 |
| CFN60103 | LGK-974 (WNT974) |
| CFN60104 | Tubastatin A |
| CFN60105 | Alectinib (CH5424802) |
| CFN60106 | BAPTA-AM |
| CFN60107 | Fulvestrant |
| CFN60108 | Verteporfin |
| CFN60109 | H 89 2HCl |
| CFN60110 | Ricolinostat (ACY-1215) |
| CFN60111 | Bisindolylmaleimide I (GF109203X) |
| CFN60112 | Go 6983 |
